THE WOODLANDS, Texas, June 15, 2011 /PRNewswire/ -- Two clinical trial studies authored by physicians affiliated with US Oncology Research and the United Network of US Oncology have been selected to be featured in the Best of ASCO to be held July 29-30 in Miami and August 5-6 in Seattle.
The American Society of Clinical Oncology (ASCO) hosted its 47th Annual Meeting June 3-7 at McCormick Place in Chicago. The Best of ASCO Meetings highlight the most relevant studies from the ASCO Annual Meeting, which is the premier educational and scientific event in the oncology community. This major medical meeting highlights the most advanced treatments in cancer care and attracts more than 26,000 cancer specialists from around the world. This year's annual meeting featured clinical trial studies that include contributions from more than 70 clinical investigators affiliated with McKesson Specialty Care Solutions | US Oncology, a division of McKesson Corporation focused on empowering the community patient care delivery system to advance the science, technology and quality of care.
Investigators affiliated with McKesson Specialty Care Solutions | US Oncology contributed to more than 60 studies that were presented at the ASCO Annual Meeting, including the two US Oncology Research affiliated physicians listed below which have been chosen to be featured in the Best of ASCO:
- Abstract #506: Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy. (